Pfizer Quick Ratio 2010-2022 | PFE

Historical quick ratio values for Pfizer (PFE) over the last 10 years.
Pfizer Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-06-30 $57.01B $47.41B 1.20
2022-03-31 $44.44B $39.27B 1.13
2021-12-31 $50.63B $42.67B 1.19
2021-09-30 $49.26B $41.80B 1.18
2021-06-30 $39.87B $35.66B 1.12
2021-03-31 $31.04B $26.65B 1.17
2020-12-31 $27.05B $25.92B 1.04
2020-09-30 $38.44B $34.15B 1.13
2020-06-30 $37.86B $32.72B 1.16
2020-03-31 $26.32B $33.89B 0.78
2019-12-31 $25.74B $37.30B 0.69
2019-09-30 $25.24B $36.97B 0.68
2019-06-30 $38.84B $32.03B 1.21
2019-03-31 $37.26B $29.42B 1.27
2018-12-31 $42.42B $31.86B 1.33
2018-09-30 $33.40B $29.01B 1.15
2018-06-30 $29.23B $32.16B 0.91
2018-03-31 $26.69B $27.37B 0.98
2017-12-31 $33.56B $30.43B 1.10
2017-09-30 $32.37B $28.22B 1.15
2017-06-30 $28.80B $27.18B 1.06
2017-03-31 $28.46B $24.86B 1.15
2016-12-31 $32.17B $31.12B 1.03
2016-09-30 $30.99B $34.76B 0.89
2016-06-30 $36.23B $32.10B 1.13
2016-03-31 $33.72B $28.74B 1.17
2015-12-31 $36.29B $29.40B 1.23
2015-09-30 $37.32B $27.85B 1.34
2015-06-30 $45.92B $24.14B 1.90
2015-03-31 $43.66B $20.22B 2.16
2014-12-31 $49.93B $21.59B 2.31
2014-09-30 $50.63B $19.92B 2.54
2014-06-30 $52.04B $21.94B 2.37
2014-03-31 $51.73B $24.79B 2.09
2013-12-31 $50.08B $23.37B 2.14
2013-09-30 $53.02B $20.37B 2.60
2013-06-30 $55.15B $23.45B 2.35
2013-03-31 $57.73B $27.54B 2.10
2012-12-31 $58.76B $29.19B 2.01
2012-09-30 $49.61B $29.13B 1.70
2012-06-30 $51.76B $30.80B 1.68
2012-03-31 $47.67B $27.09B 1.76
2011-12-31 $54.21B $28.91B 1.88
2011-09-30 $54.31B $27.86B 1.95
2011-06-30 $51.89B $30.47B 1.70
2011-03-31 $49.78B $29.17B 1.71
2010-12-31 $52.74B $28.64B 1.84
2010-09-30 $45.32B $24.17B 1.88
2010-06-30 $41.59B $24.68B 1.69
2010-03-31 $39.78B $25.92B 1.54
2009-12-31 $49.27B $37.23B 1.32
2009-09-30 $68.73B $23.99B 2.87
2009-06-30 $66.56B $26.11B 2.55
2009-03-31 $49.80B $23.34B 2.13
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.597B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $429.503B 16.35
Eli Lilly (LLY) United States $307.239B 38.96
AbbVie (ABBV) United States $237.296B 10.08
Novo Nordisk (NVO) Denmark $225.460B 29.74
Merck (MRK) United States $218.166B 11.39
Novartis AG (NVS) Switzerland $168.180B 12.40